Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.

Cancer Commun (Lond)

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.

Published: October 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504141	PMC
http://dx.doi.org/10.1002/cac2.12206	DOI Listing

Publication Analysis

clinical outcomes

outcomes second-line

second-line treatment

treatment first-line

first-line vegfr-tki

vegfr-tki failure

failure patients

patients metastatic

metastatic renal

renal cell

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!